BioCentury
ARTICLE | Company News

Cantabio, University of Antioquia deal

June 27, 2016 7:00 AM UTC

Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partne...